Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Spyre Therapeutics Inc SYRE

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and... see more

Recent & Breaking News (NDAQ:SYRE)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

PR Newswire 10 hours ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire 2 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire 4 days ago

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire 5 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire 5 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

PR Newswire 6 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire 8 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire 9 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire 10 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

PR Newswire 12 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire 13 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire December 24, 2024

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

PR Newswire December 18, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire December 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire December 16, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire December 15, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire December 13, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire December 11, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation

Accesswire December 4, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

PR Newswire December 3, 2024